Author: Gianpiero Pescarmona
Date: 04/11/2009


Cell Cycle. 2009 Jun 15;8(12):1820-1. Epub 2009 Jun 15.
Forever young, slim and fit: rapamycin to the rescue.

Darzynkiewicz Z.

Brander Cancer Research Institute, New York Medical College, Valhalla, NY, USA. Z_DARZYNKIEWICZ@nymc.edu

Comment on:

* Cell Cycle. 2009 Jun 15;8(12):1888-95.

PMID: 19471126 [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances
Publication Types:

* Comment

MeSH Terms:

* Animals
* Autophagy/drug effects*
* Autophagy/physiology
* Cell Aging/drug effects*
* Cell Aging/physiology
* Cell Cycle/drug effects
* Cell Cycle/physiology
* Cyclin-Dependent Kinase Inhibitor p16/biosynthesis*
* Cyclin-Dependent Kinase Inhibitor p21/biosynthesis*
* Humans
* Protein Kinases/drug effects*
* Protein Kinases/metabolism
* Signal Transduction/physiology
* Sirolimus/pharmacology*


* Cyclin-Dependent Kinase Inhibitor p16
* Cyclin-Dependent Kinase Inhibitor p21
* Sirolimus
* mTOR protein
* Protein Kinases

LinkOut - more resources
Full Text Sources:

* Landes Bioscience


* LinkOut Holdings

Supplemental Content
Click here to read Click here to read
Related articles

* Rapamycin decelerates cellular senescence.

Cell Cycle. 2009 Jun 15; 8(12):1888-95. Epub 2009 Jun 1.

[Cell Cycle. 2009]
* Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration.

Cell Cycle. 2009 Jun 15; 8(12):1883-7. Epub 2009 Jun 21.

[Cell Cycle. 2009]
* G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.

Am J Physiol Cell Physiol. 2004 Aug; 287(2):C281-91. Epub 2004 Mar 17.

[Am J Physiol Cell Physiol. 2004]
* ReviewRapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies.

Cell Death Differ. 2009 Jan; 16(1):46-56. Epub 2008 Jul 18.

[Cell Death Differ. 2009]
* ReviewThe role of mTOR inhibition in augmenting radiation induced autophagy.

Technol Cancer Res Treat. 2007 Oct; 6(5):443-7.

[Technol Cancer Res Treat. 2007]
* » See reviews... | » See all...

Patient drug information

* Sirolimus (Rapamune®)

Sirolimus is used in combination with other medications to prevent rejection of kidney transplants. Sirolimus is in a class of medications called immunosuppressants. It works by suppressing the body's immune system.
* Source: AHFS Consumer Medication Information

Zotarolimus, sirolimus e paclitaxel, validi contro Stemi
Zotarolimus, sirolimus e paclitaxel risulterebbero parimenti efficaci nel trattamento di pazienti con infarto in corso e sopraslivellamento del tratto ST (STEMI). E' quanto emerge da uno studio pubblicato su American Journal of Cardiology, che in questi pazienti ha voluto confrontare gli outcome derivanti dall'impiego di stent a rilascio dei tre differenti farmaci. In 12 centri sono stati reclutati 328 pazienti Stemi abbinati per quadri clinici e angiografici e poi randomizzati a ricevere zotarolimus, sirolimus e paclitaxel. Dopo 8 mesi dall'impianto degli stent, nel gruppo trattato con sirolimus rispetto a quelli con zotarolimus e paclitaxel, sia la "in-segment late loss (0,28 ± 0,42 vs 0,46 ± 0,48 vs 0,47 ± 0,50 mm, rispettivamente) sia l'incidenza di restenosi sono risultate inferiori (2,7% vs 15,9% vs 12,3%, rispettivamente). In aggiunta, dopo 12 mesi la frequenza di Mace (eventi cardiaci maggiori sfavorevoli) è risultata pari a 11,3%, 8,2%, e 8,2% con zotarolimus, sirolimus e paclitaxel, rispettivamente. Infine, nessuna differenza tra i tre farmaci è stata riscontrata nel tasso di mortalità, d'infarto miocardico ricorrente e di rivascolarizzazione del vaso target (L.A.).

American Journal of Cardiology 2009; 104 (10): 1370-76

Tacrolimus treatment increases bone formation in patients with rheumatoid arthritis. 2009

Tacrolimus is a calcineurin inhibitor, and it is used for the treatment of rheumatoid arthritis (RA). It works by inhibiting nuclear factor of activated T cells and inducting immunosuppression. This study aims to evaluate the influence of tacrolimus on the bone metabolism of patients with RA. Twenty-eight RA patients in three centers received tacrolimus 3 mg once daily for 24 weeks. Blood samples for evaluating bone metabolism and cytokines were collected at Weeks 0 and 24. We measured the serum C-telopeptide of type I collagen (sCTx-I), osteocalcin and inflammatory cytokines. We analyzed the data using the Kruskal-Wallis test and Spearman's correlation. IL-2 and IL-6 were significantly decreased after the administration of tacrolimus (p = 0.027 and p = 0.024). There was no significant difference in the serum level of sCTx-I before and after treatment. The level of serum osteocalcin at Week 24 was significantly increased compared to the level at Week 0 (p = 0.002). The increase of osteocalcin was correlated with the reductions of IL-2 and IFN-γ (r = 0.405, p = 0.033 and r = 0.380, p = 0.046, respectively). Tacrolimus treatment increased bone formation markers in RA patients. This suggests that tacrolimus may play a role to inhibit bone erosion by increasing bone formation as well as improving the clinical symptoms of RA.

AddThis Social Bookmark Button